Compare Boeing Co (BA) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boeing Co vs Quest Diagnostics Inc — how do they compare? Boeing Co trades at $231.25 (market cap $184.35B), while Quest Diagnostics Inc trades at $237.49 (market cap $26.21B). The key difference: Boeing Co is far larger — about 7× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| BA | DGX | |
|---|---|---|
Market Cap | $184.35B | $26.21B |
Volume | 7,591,579 | — |
Sector | Industrials | Health |
52-Week High | $252.15 | $238.50 |
52-Week Low | $179.12 | $173.49 |
Enterprise Value | $210.23B | $31.97B |
Dividend Yield | 0.03% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $230.11, down 1.15% on the day, with a bullish technical signal and strong analyst support. The company shows improving fundamentals with 2025 revenue of $89.46 billion and net income of $2.24 billion, marking a return to profitability after three years of losses. Recent news highlights Boeing's strategic divestiture of non-core aviation technology units to Archer Aviation, allowing greater focus on core aerospace operations.
The outlook remains positive with 67% analyst buy ratings and a $280.83 consensus price target representing 22% upside potential. Key risks include execution challenges in production ramp-up, high debt levels, and competitive pressures. Earnings momentum is mixed with a recent Q2 2026 miss but beats in prior quarters, requiring monitoring of Q3 2026 results due soon.
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
